
Sign up to save your podcasts
Or


From a graveyard shift in a generic drug lab to leading quality for one of the most advanced cell therapy programs on the planet - Mike Ruane's story is one every quality professional needs to hear.
In today's episode I was joined by Mike Ruane, Head of Quality for In Vivo CAR-T at Bristol Myers Squibb.
I really wanted to speak to Mike because his career is one of the more fascinating journeys I have come across in quality leadership. He has spent nearly two decades within what is effectively the same organisation, yet has lived through multiple acquisitions, spin-offs and complete pivots in therapeutic modality - each time emerging in a stronger, more interesting role than before.
Mike began his career at APP Pharmaceuticals on a midnight QC shift, testing in-process samples on a graveyard schedule. From there, he followed the Abraxane asset into aBraxis Bioscience, built out supplier quality relationships across Central and South America, and eventually relocated from Chicago to New Jersey when Celgene consolidated its operations.
That move opened the door to something entirely new - a CAR-T therapy program called BB2121 - a field Mike had never worked in and knew little about. Eight years later, he is now heading quality for in vivo CAR-T, one of the most cutting-edge modalities in all of biopharma.
What makes Mike Ruane such a compelling guest is not just the breadth of his experience but his philosophy. He is a first-principles thinker who has thrived precisely because he never assumed the existing process was the right one. He asks the uncomfortable questions, encourages his team to do the same, and believes deeply that curiosity is the most underrated skill in quality.
We talk about the following:
How working in a lean generic drug environment early in his career shaped his mindset forever
Navigating multiple acquisitions and spin-offs within a single career arc
What it takes to step into an entirely new therapeutic modality with no prior experience
Why curiosity and asking the right questions is the real engine of career growth in quality
How he interviews candidates and what most people get wrong when they are being interviewed
Mike Ruane is a thoughtful, pragmatic quality leader who understands how to balance compliance, collaboration and business reality in complex development environments.
If you are a quality professional working in an early-stage biotech and trying to build the right systems with limited resources, then this episode is for you.
Thank you Mike Ruane for sharing your incredible journey.
Hope everyone enjoys the show.
Timestamps:
(00:00) Introduction to Mike's Career Journey
(02:01) Transitioning Through Acquisitions and Roles
(06:39) Navigating Supplier Quality and External Partnerships
(11:05) The Shift to CAR T Therapy
(16:05) The Importance of Asking Questions
(20:48) Advice for Future Generations
CAR-T Saved Her Life. Why Can’t Most Patients Access It?
In today’s episode I was joined by Laurie Adami, cancer survivor, patient advocate, and one of the most impactful voices I’ve had on the podcast.
I first spoke to Laurie a couple of years ago, and her episode is still one of the most listened to we’ve had.
Laurie went through a 12-year cancer journey, six lines of therapy, multiple relapses, clinical trials… and ultimately, in 2018, her 7th treatment, CAR T-cell therapy which saved her life and finally for the first time in 12 years put her in a complete remission.
Now, two years on, she’s back.
Still in a complete remission and requiring no further treatment nearly 8 years post CAR T infusion, Laurie is now considered cured even though her cancer is still labeled incurable.
But what stood out to me in this conversation is that while the science has progressed… many of the systemic challenges patients face haven’t.
We talk about the following:
· What life actually looks like after being “cured” of cancer
· The long-term side effects of 12 years of treatment
· Why most biotech and pharma professionals have never spoken to a patient
· The reality behind “patient centricity” in the industry
· Why 80% of eligible patients still can’t access CAR-T therapy
· The biggest bottlenecks in access - awareness and insurance
· The financial burden of cancer treatment in the US
· Where real progress is being made in cell and gene therapy
· The future of CAR-T in autoimmune diseases and beyond
· Laurie’s memoir and why every biotech employee should read it
This is an honest conversation about the gap between scientific progress and real-world patient impact.
A huge thank you to Laurie for returning to the show and tell her story again! The work she is doing to help raise awareness is inspiring, and I’d urge anyone to connect with Laurie and follow her journey.
If you work in biotech, pharma, healthcare, or you’d like to learn more about the challenges this industry still faces… this is one you need to hear.
Timestamps:
(00:00) A Journey of Survival and Remission
(02:28) Life After CAR-T: Misconceptions and Realities
(05:35) The Ongoing Battle: Side Effects and Daily Life
(08:30) Patient Advocacy: Bridging the Gap with Pharma
(11:00) The Disconnect: Patient Needs vs. Industry Understanding
(13:48) Access and Awareness: The Challenges of CAR-T Therapy
(16:36) The Future of CAR-T: Innovations and Progress
(19:30) Writing a Memoir: Sharing the Patient Experience
Perseverance, perspective and people-first leadership in a global quality role.
In today's episode I was joined by Burak Begen, Head of Global Manufacturing Quality at Siemens Healthineers.
I really wanted to speak to Burak because he’s built his career across multiple countries, cultures and challenges, and now leads quality across global manufacturing sites. His journey gives a very real view of what it actually takes to operate at that level.
Burak’s career hasn’t been linear or easy. From starting his career in Turkey, moving to the US for his PhD, rebuilding his career from scratch, and navigating setbacks like job losses and site closures - his story is defined by perseverance and resilience.
What stood out is how those experiences shaped the way he leads today. He leads from the front, sets high standards, but always stays close to his teams. Whether it’s staying late to close records or travelling globally to connect with people on site, his leadership is grounded in accountability and support.
We talk about the following:
If you are a quality professional managing multiple sites a leader struggling with KPIs, culture or engagement across sites, or someone who wants to step into a larger global role, then this episode is for you.
Thank you Burak for sharing your incredible journey.
Hope everyone enjoys the show.
Timestamps:
(00:00) Introduction to Burak Begen
(06:00) The Importance of Quality in Leadership
(10:39) Cultural Influences on Leadership
(16:11) Navigating Time Zones and Cultural Differences
(21:03) The Role of KPIs in Quality Management
(27:51) Looking Ahead: Future Aspirations
Great quality leaders don’t just build systems - they build people, culture and confidence.
In today's episode I was joined by Melodie Bryce, Chief Quality Officer at Kincell Bio.
Melodie’s journey is a brilliant example of how diverse experience across manufacturing, supply chain, training and quality can shape a well-rounded quality leader
What stood out most is her approach to leadership. Melodie focuses heavily on building strong teams, developing future leaders and creating an environment where people are supported but also expected to take ownership. She combines high standards with a genuine commitment to coaching and mentorship.
We talk about the following:
· How to assess a quality organisation when you first join
· Why hiring “stronger than you” is critical to building high-performing teams
· What makes a great quality leader in fast-growing biotech environments
· The importance of being a self-starter in quality roles
· How to develop future leaders through coaching and mentorship
· What to look for in the first two weeks of hiring someone
· Leading through remediation and why it accelerates growth
· Building a quality culture where everyone takes ownership
· Balancing compliance with real-world decision making in cell therapy
· Why “digging deep” is the foundation of leadership success
Melodie is a thoughtful, pragmatic quality leader who understands how to balance compliance, collaboration and business reality in complex development environments.
If you are a quality leader looking to develop stronger teams and future leaders, then this episode is for you.
Thank you Melodie for sharing your incredible journey.
Hope everyone enjoys the show.
Timestamp:
(00:00) Introduction to Quality Leadership
(04:01) Challenges in Quality Leadership
(06:15) Developing Future Leaders
(08:33) Hiring for Success
(11:01) Assessing New Hires
(13:57) Leadership Evolution
(16:04) Cultural Insights in Quality
(18:56) Advice for Aspiring Leaders
If you are the first quality hire in a startup, your job is not to build everything at once.
Your job is to build the right things first.
That was one of the clearest takeaways from my conversation with Rex Ready on Let’s Talk Quality.
A few practical points he shared stood out:
· Follow the path of the product
· Understand the patient experience
· Focus first on what directly affects patient safety
· Build procedures around processes that already work
· Prioritise quality investment based on stage, modality, and risk
In early-phase environments, it is easy to create a long list of things you would like to have.
An EQMS.
A fuller audit programme.
More formal vendor oversight.
A bigger team.
All of that matters.
But not all of it matters equally on day one.
Strong quality leadership is about judgment. It is about knowing what must be in place now, what can come next, and how to build trust while you do it.
That is especially true in cell and gene therapy, where complexity is high and patient impact is immediate.
A very strong conversation with Rex, and a useful one for anyone building quality in a lean biotech environment.
Timestamps:
(00:00) Introduction
(02:30) From Funeral Director to Biotech: A Unique Path
(05:47) Early Experiences in Quality Control
(07:26) Leadership in Quality: Building Relationships
(09:57) Vision for the Future: Drug Development and Quality
(15:04) Building Effective Relationships in Quality
(17:59) Prioritizing Quality in a Lean Team
(22:58) Planning for Future Growth in Quality
(28:01) Reflections on Cell and Gene Therapy
Quality is changing. The systems are getting smarter, the data is getting bigger, and the people side is still the hardest part.
This week, I sit down with Dennis Rodman, Senior Director of Quality Management Systems and Digital Compliance at Intellia Therapeutics.
Dennis brings a rare perspective to quality. With 13 years at BMS across operations, technical services, and quality, he now helps a gene editing company prepare for its first commercial product.
In this episode, we explore:
A practical, honest conversation for anyone working at the intersection of quality, systems, and people.
Timestamps:
(00:00) Introduction and Background
(05:04) Quality Management Systems and Operations
(09:59) Stakeholder Engagement and Change Management
(15:12) The Role of IT in Quality Management
(21:02) Cultural Shifts and Data Sharing
(23:34) Advice for Aspiring Quality Leaders
(26:01) Future of Biotech and Quality Management
From accidental quality professional to global quality leader - Valerie Brown's story is one of courage, curiosity, and conviction.
In today's episode I was joined by Valerie Brown, Head of Global Quality Assurance and Compliance at Thermo Fisher Scientific's Clinical Research Group.
I really wanted to speak to Valerie because she brings something different to the quality leadership conversation. Yes, she has held senior quality roles across innovator companies, CDMOs, and now one of the largest CROs in the world. But what makes her story compelling is how she got there - and what she learned along the way.
Valerie didn't plan to work in quality. At 22, she was asked to be a scribe for an FDA inspection. The host fell ill on the day. She stepped in - no preparation, no safety net - and handled it.
Someone told her she had a knack for it. She wasn't sure she agreed. She still wanted to be in the lab, in manufacturing, doing what she knew. But that moment planted a seed.
What followed was a career that took her across CDMOs, innovator companies including Gilead Sciences, and now Thermo Fisher - where she leads global quality assurance and compliance for the clinical research group. She has sat on both sides of the table, as sponsor and as service provider, and that experience shapes everything about how she leads.
We talk about the following:
Valerie Brown is a highly accomplished global quality leader whose career is a masterclass in adaptability, influence, and patient-centric thinking. She leads with purpose, develops people with intention, and approaches every challenge with the mindset of a problem solver - exactly the kind of leader our industry needs more of.
Thank you Valerie for sharing your incredible journey. Hope everyone enjoys the show!
Timestamps:
(00:00) Introduction to Valerie Brown and Her Journey
(02:59) Valerie's Leadership Philosophy and Style
(06:00) Transitioning from Innovator to CRO: Insights and Challenges
(11:04) Quality Assurance in Clinical Research: A New Perspective
(13:58) Building a Quality Organization: Strategies and Goals
(20:55) The Role of AI in Quality Management
(24:18) Future Goals and Challenges in Quality Assurance
(29:04) Advice for Aspiring Quality Leaders
What if the leader you become is shaped less by your title, and more by the life you’ve lived?
In today's episode I was joined by Dana Adcock, Quality Consultant and former Senior Director of Quality Systems.
I really wanted to speak to Dana because she brings something different to the quality leadership conversation. Yes, she has decades of experience leading global audit and quality systems teams. But what makes her story powerful is how openly she connects her personal journey to the leader she has become.
Dana shares how growing up as an adult child of alcoholics shaped her early career. Avoiding conflict. Playing small. Hiring people who thought like her. Shying away from leadership roles despite being promoted into them.
Over time, through personal hardship, therapy, motherhood, and reflection, she stepped into leadership differently. More intentional. More courageous. More authentic.
We talk about the following:
· How early life patterns show up in leadership behaviour
· Why many capable professionals avoid management roles
· Moving from conflict avoidance to confident, purpose-led leadership
· Building diverse teams instead of hiring people “just like you”
· The mindset shift that happened during her “midlife awakening”
· How adopting her daughter Abby changed how she leads and advocates
· The link between personal resilience and professional courage
· Showing up authentically on LinkedIn and why it felt terrifying
· What “living the fourth quarter intentionally” really means
· Advice for quality professionals who feel pressure to hide parts of themselves
Dana is a thoughtful, courageous and deeply reflective leader who demonstrates that strength in quality leadership isn’t about technical authority alone – it’s about self-awareness, integrity and the willingness to grow.
Thank you Dana for sharing your incredible journey.
Hope everyone enjoys the show!
Timestamps:
(00:00) Introduction
(01:43) Early Challenges in Career Growth
(10:37) Midlife Awakening
(18:06) Embracing Authenticity in Leadership
(28:08) The Importance of Being Seen
In today’s episode, Hemish was joined by Anthony Mire-Sluis, Head of Global Quality at Gilead.
Tony because has lived quality from every angle - UK government and regulatory work, a stint at the FDA, and then senior global leadership roles in major pharma. That perspective is rare, and it shows in how he builds teams and drives change.
Tony’s journey is a brilliant example of how strong quality leadership is less about having all the answers, and more about building trust, listening properly, and creating systems that let people do their best work.
He talks about the following:
• How Tony’s science background (immunology, genetics, and a PhD) shaped the way he leads quality
• What 10 years in government taught him about great vs poor regulatory filings - and why he moved into industry
• The difference between leading a US-centric quality organisation vs a truly global one
• Why building a trusted leadership team is the non-negotiable for running global quality at scale
• How Tony uses his first 90 days: listening, due diligence, and getting under the skin of the culture
• Why he starts transformation from the shop floor - not from the senior leadership layer
• Digital and AI in quality: fix the process first, then digitise (otherwise you just create a clunky digital version)
• How to reduce firefighting and move quality from reactive to proactive - with better workflows and connected systems
• Managing resistance to change and bringing people along early so adoption sticks
• Advice for aspiring quality leaders: networking, knowing yourself, and broadening your experience across quality
Anthony Mire-Sluis is an authentic, people-first quality leader with a rare blend of regulatory depth and big pharma operational experience - and he’s exactly the kind of leader who makes quality a true enabler of the business.
Thank you Tony for sharing your incredible journey.
Hope everyone enjoys the show!
In today’s episode, Hemish was joined by Ed Armstrong and Jon Voss, two Quality leaders who’ve both worked across early-stage, clinical, and complex biotech environments.
Ed and Jon share what they’re seeing on the ground - from funding pressure and modality shifts, to how regulators are engaging, and where Quality leaders are gaining (or losing) influence.
They talk about the following:
Ed and Jon bring a huge amount of perspective, humility, and real-world insight to this discussion. This is a conversation for anyone leading Quality through uncertainty and trying to balance patient safety, speed, and sustainability.
Hope everyone enjoys the show!